N/A N=12 Aspirin and Compression Devices for VTE Prophylaxis in Orthopaedic Oncology
Bone Metastases · Musculoskeletal Cancer · Soft Tissue Sarcoma
Primary: DVT Incident Rate — 0; 0 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Early Phase 1 N=21 New Tool to Enhance Post-stroke Upper Extremity Disability
Stroke
Primary: Change in Action Research Arm Test (ARAT) Total Score From Baseline to Post-Intervention — 0.72; 0 Units on a scale
Phase 4 N=24 Effect of Deep BLock on Intraoperative Surgical Conditions
Prostate Hypertrophy · Renal Disease
Primary: Surgical Rating Scale — 4; 4.7 units on a scale (1-5) — p=<0.001
Phase 4 N=28 Treatment of Upper Extremity Deep-Vein Thrombosis
Deep-Vein Thrombosis
Primary: Percentage of Participants That Died at 3 Months — 8; 0 percentage of participants
N/A N=20 Feasibility of Home-based Virtual Reality Rehabilitation for the Upper Extremity in Subacute and Chronic Stroke
Stroke
Primary: Device Use — 27 days
Phase 2 N=20 Rosuvastatin to Lower Circulating Tissue Factor Bearing Microparticles in Metastatic Breast Cancer
Breast Cancer
Primary: Mean Change of Tissue Factor Bearing Microparticles — 102; -618 microparticles per microliter
N/A N=28 Throwers Ten Exercises On Upper Extremity Function and Explosive Power in Wheelchair Basketball and Basketball Players
Upper Extremity Injury · Sport Injury · Shoulder Pain
Primary: Measurement of Muscle Strength (Absolute Values Are Being Reported) — 3.9; 5.1; 5.7; 7.4 kg
Phase 2 N=30 Low-Dose Alteplase to Treat Blood Clots in Deep Leg Veins
Acute Deep Venous Thrombosis of the Lower Extremity
Primary: Number of Participants With Restored Venous Function — 28 participants
N/A N=100 Detection of Colonic Polyps Via a Large Scale Artificial Intelligence (AI) System
Colonic Polyp
Primary: Number of Additional Polyps Detected by the DEEP System in Real Time Colonoscopy — 0.89 Added polyps detected per colonoscopy
Phase 3 N=841 A Study to Evaluate the Efficacy and Safety of Rivaroxaban Venous Thromboembolism (VTE) Prophylaxis in Ambulatory Cancer Participants
Neoplasms
Primary: Percentage of Participants With Time to First Occurrence of Primary Efficacy Endpoint (Composite and Components) — 8.79; 5.95; 1.90; 2.14 Percentage of participants…
Phase 4 N=90 Rivaroxaban With Diosmin in Long-term Treatment of Deep Vein Thrombosis
Deep Vein Thrombosis · Postthrombotic Syndrome
Primary: Number of Participants With Postthrombotic Syndrome as Determined by Villalta Score — 3; 22 Participants — p=<0.0001
N/A N=10 Exercise-primed Upper Extremity Motor Practice in Chronic Stroke
Stroke
Primary: Change in Upper Extremity Impairment as Assessed by the Fugl-Meyer Assessment - Upper Extremity — 2.6 units on a scale — p=.15
Phase 2 N=70 Enoxaparin Thromboprophylaxis in Cancer Patients With Elevated Tissue Factor Bearing Microparticles
Advanced Pancreatic, Colon, Lung, Gastric and Ovarian Cancer
Primary: 2-Month Cumulative Incidence of VTE — 5.6; 27.2; 7.2 percent probability — p=0.06
N/A N=24 Adjunct Low Frequency Repetitive Transcranial Magnetic Stimulation With Physiotherapy Enhance Upper Extremity Function Restoration
Stroke
Primary: Change of Cortical Excitability From Baseline to at 4th Weeksand 12th Weeks Training in Motor Evoked Potential at 120% Resting MotorThreshold at Affected Hand — 258.3…
Phase 2 N=30 Micro-mobile Foot Compression and Diabetic Foot
Diabetes · PAD · Lower Extremity Edema
Primary: Change in Balance From Baseline to 4 Weeks — 0.94; 0.76 cm